Efficacy and safety of pirarubicin hot perfusion combined with systemic chemotherapy in the treatment of advanced bladder cancer
10.13699/j.cnki.1001-6821.2015.03.008
- VernacularTitle:吡柔比星热灌注联合全身化疗治疗晚期膀胱癌的疗效与安全性评价
- Author:
Song-Tao LUO
1
;
Ying-Hong WANG
;
Da-Zhong LIAO
;
Ming-Jie WANG
;
Xu-Kun LI
;
Wei TANG
;
Xing LIU
;
Jing-Wei KE
;
Yi-Quan TANG
Author Information
1. 泸州医学院附属中医医院 外五科
- Keywords:
bladder cancer;
pirarubicin;
hot perfusion chemotherapy;
clinical efficacy;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2015;(3):184-186
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effects and safety of pirarubicin hot perfusion chemotherapy combined with gemcitabine and cisplation on advanced bladder cancer.Methods Forty -seven patients with ad-vanced bladder cancer were divided into control group ( 24 cases ) and treatment group (23 cases).Patients in control group were treated with gemcitabine l 000 mg · m-2 on day 1 and day 8 and cisplation 30 mg· m-2 on day 2, 3 and 4 through intravenous injection with 4 cycles of chemotherapy (28 days as a cycle).Patients in treatment group were treated with pirarubicin 20 mg through bladder infusion on the basis of the treatment of control group, once a week for 8 weeks.The data of clinical efficacy and adverse reactions were evaluated between the two groups.Results After 4 cycles chemotherapy, the objective response rate of treatment group ( 78.3%) was much higher than that in control group(41.7%) ( P<0.05).The occurrence rate of adverse drug reac-tions in treatment group and control group were 17.4%and 20.8%, and there was no statistical differences between the two groups ( P>0.05 ).Conclusion Pirarubicin hot perfusion chemotherapy combined with gemcitabine and cisplation can significantly improve the efficacy of advanced bladder cancer without increasing the adverse reactions.
